drugset / Trial / NCT00755846

Safety and Efficacy Study of Alogliptin on Glycemic Control in Subjects With Type 2 Diabetes.

NCT00755846

Phase 2 Completed 265 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the safety and efficacy of alogliptin, once daily (QD), compared to diet and exercise, sulfonylurea, metformin and a combination of sulfonylurea and metformin for treating subjects with type 2 diabetes.

Timeline

Start
2005-03
Primary completion
2005-10
Completion
2005-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Alogliptin Unknown 6.25 mg Oral
Subject Alogliptin Unknown 12.5 mg Oral
Subject Alogliptin Unknown 25 mg Oral
Subject Alogliptin Unknown 50 mg Oral
Subject Alogliptin Unknown 100 mg Oral

Indications